Drotrecogin alfa (activated): real-life use and outcomes for the UK

  title={Drotrecogin alfa (activated): real-life use and outcomes for the UK},
  author={Kathryn M. Rowan and Catherine A Welch and Emma North and David A Harrison},
  journal={Critical Care},
  pages={R58 - R58}
INTRODUCTION In March 2001, the results of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study were published, which indicated a 6.1% absolute reduction in 28-day mortality. Drotrecogin alfa (activated; DrotAA) was subsequently approved for use in patients with severe sepsis. METHODS In December 2002, critical care units in England, Wales and Northern Ireland were invited to participate in an audit of DrotAA. Data for each infusion of DrotAA were… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 25 extracted citations


Publications referenced by this paper.
Showing 1-10 of 26 references

Cost - effectiveness of activated protein C in real - life clinical practice

  • E Abraham, PF Laterre, +12 authors WL Macias
  • Crit Care
  • 2007

Similar Papers

Loading similar papers…